SCHEMBL21130168

SCHEMBL21130168

Fc1cc2cc(Cl)c(Cl)nc2cc1Br

nearest known ligand 0.39

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 4/20 0.39
KDM1B Q8NB78 3/20 0.39
KCNH2 Q12809 2/20 0.31
PIK3R1 P27986 1/20 0.30
PIK3CA P42336 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29911221 1.00 KDM1A (0.39) KDM1AKDM1BKCNH2PIK3R1PIK3CA
SCHEMBL29911222 0.81 KDM1A (0.37) KDM1AKDM1B
SCHEMBL21129801 0.81 KDM1A (0.37) KDM1AKDM1B
SCHEMBL31071314 0.81 CYP1A2 (0.41) KDM1AKDM1B
SCHEMBL406362 0.79 TDP1 (0.37) KDM1AKDM1BKCNH2PIK3R1PIK3CA
SCHEMBL13230128 0.78 KMT2A (0.37)
SCHEMBL9775902 0.76 KEAP1 (0.56)
SCHEMBL26931427 0.74 KDM1A (0.33) KDM1AKDM1B
SCHEMBL30682774 0.74 KDM1A (0.33) KDM1AKDM1B
SCHEMBL23544620 0.72 NQO1 (0.37) KDM1AKDM1BKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11952380-B2 Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors LUPIN LIMITED (IN) 2024-04-09 US disclosed
EP-3724190-B1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS LUPIN LTD (IN) 2022-07-06 EP disclosed
EP-3724190-B1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS LUPIN LTD (IN) 2022-07-06 EP disclosed
US-20210163486-A1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS LUPIN LIMITED (IN) 2021-06-03 US disclosed
US-20210163486-A1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS LUPIN LIMITED (IN) 2021-06-03 US disclosed
WO-2019116302-A1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS LUPIN LIMITED (IN) 2019-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210163486-A1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 KDM1A 41/4885KDM1B 36/4885KCNH2 3433/4885
US-11952380-B2 Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors PRMT5, PRMT1, PRMT3 KDM1A 41/4885KDM1B 36/4885KCNH2 3433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.